# Samsung Biologics Faces Prolonged Labor Strike Amid Contract Manufacturing Expansion Unionized workers initiate a three-week partial strike as wage negotiations remain deadlocked for months. - **Source:** [The Korea Times – All](https://www.koreatimes.co.kr) - **Published:** 2026-11-06 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/e91c2244-2de4-4105-858b-eae39f973355 ## Ongoing Labor Dispute Escalation Samsung Biologics unionized workers launched a partial strike this Friday, marking a significant escalation in their ongoing labor dispute. Negotiations regarding wages and collective bargaining have remained deadlocked for over six months. This industrial action, which avoids large public rallies, is currently scheduled to continue through November 27, impacting critical internal operations. ## Scope of Workforce Participation Approximately 400 employees are actively participating in this three-week strike action. This figure represents roughly 10 percent of the union's total membership of 4,000 workers. The participants are drawn from essential departments, including quality control testing, quality assurance, logistics, and production, which are vital for maintaining the company's complex drug manufacturing schedules. ## Historical Context of Negotiations The current labor tensions trace back to March, when both management and union representatives officially declared a breakdown in their 2026 wage and collective bargaining talks. This impasse led to a previous partial strike in April, which was notably the first such labor action since the company was originally established back in 2011. ## Operational Risks for Production The involvement of staff from quality control and production departments raises concerns regarding the company's ability to meet delivery timelines. As global competitors aggressively expand their own contract drug manufacturing capabilities, any disruption in output could threaten Samsung Biologics' reputation. Reliability remains a primary competitive advantage in the highly regulated pharmaceutical supply chain sector. ## Competitive Market Pressures Samsung Biologics operates in a high-stakes environment where global rivals are rapidly scaling their manufacturing capacities. The company must balance internal labor demands with the necessity of maintaining consistent drug volumes for international clients. Prolonged disputes risk creating uncertainty for partners who rely on the firm for time-sensitive, large-scale pharmaceutical production requirements. ## Impact on Quality Assurance Quality assurance and testing are non-negotiable pillars of pharmaceutical manufacturing, requiring strict adherence to regulatory standards. By pulling workers from these specific departments, the union exerts significant pressure on management's operational capacity. Any failure to maintain these standards during the strike could have long-term regulatory consequences for the company's manufacturing licenses. ## Management and Union Stance The breakdown in negotiations reflects deep-seated disagreements over compensation structures and collective bargaining terms. While the union seeks improved conditions, management faces the challenge of maintaining cost competitiveness in a global market. Both parties remain at an impasse, with the current strike serving as a tactical tool to force a return to meaningful dialogue. ## Future Outlook and Implications The outcome of this three-week strike will likely set a precedent for future labor relations at Samsung Biologics. If the dispute continues beyond November, the company may face increased scrutiny from stakeholders regarding its operational stability. Resolving these internal conflicts is essential for the firm to sustain its growth trajectory within the global biopharmaceutical industry. ## Sources covering this story - https://www.koreatimes.co.kr/business/companies/20261106/samsung-biologics-labor-dispute-drags-on-as-union-stages-another-strike?utm_source=rss — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._